Uni-Bio Science's strategic priorities :
Focus on diabetes and diabetes related complications in areas such as ophthalmology and dermatology :
To grow our diversified portfolio of innovative treatments and healthcare solutions through partnerships that address
high unmet medical need to patients in China
To realise the broad growth opportunities presented to us by the changing dynamic of the Chinese healthcare market
To increase the breadth of our sales coverage beyond the key provinces where we already have a strong geographic
We employ two specific elements one focused internally (solidifying foundation) and the other focused externally (maximising value).
Our ultimate goal is to build a leading, sustainable organisation that delivers shareholder value by efficiently executing a number
of growth strategies.
Our strategy is driven by our team of highly experienced professionals. A distinct combination of local knowledge and international
experience equips us well to grow as a leading domestic healthcare company with a global outlook.
Uni-Bio Science's strength as an experienced Chinese healthcare company will enable the Group to leverage
the growth drivers available to it in China, one of the world's largest healthcare markets.
Increasing healthcare spending
Healthcare reforms which will recognise and reward genuine innovation
Innovative products demonstrating resistance to downward pricing pressures
The launch of innovative proprietary medicines, combined with the successful execution of our partnering strategy, will spur growth
in our business, reduce risk and create long-term value for shareholders.